swine flu monitor

BOSTON (Reuters) - U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's Fosamax and certain thigh bone fractures.

LONDON (Reuters) - Only half of patients at high risk of heart disease are given the right targets for cutting their cholesterol and millions may suffer heart attack or stroke due to doctors' poor advice, scientists said on Thursday.

WASHINGTON (Reuters) - Recent new powers have helped the U.S. Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials said on Wednesday.

BOSTON (Reuters) - U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's Fosamax and certain thigh bone fractures.

BOSTON (Reuters) - U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's Fosamax and certain thigh bone fractures.

WASHINGTON (Reuters) - Two studies published on Wednesday show it is possible to sequence the entire gene maps of families with inherited diseases and pinpoint the offending bit of DNA.

NEW YORK (Reuters Health) - If you're pregnant and have had a cesarean section before, chances are you'll have one again. In at least one-third of US hospitals, a repeat cesarean is the only option, and nine in 10 women end up getting one -- a fact that had experts worried at a national conference this week on vaginal birth after cesarean, or VBAC.

WASHINGTON (Reuters) - Recent new powers have helped the U.S. Food and Drug Administration combat contaminated medications, counterfeit pills and other safety woes, but more work is needed to address lingering concerns about drug risks, FDA officials said on Wednesday.

WASHINGTON (Reuters) - The most commonly used tool for detecting prostate cancer, routine PSA screening, has become "a hugely expensive public health disaster," its discoverer said on Wednesday.

WASHINGTON (Reuters) - The most commonly used tool for detecting prostate cancer, routine PSA screening, has become "a hugely expensive public health disaster," its discoverer said on Wednesday.